• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
RCE 2.27% 43.0¢

RECCE PHARMACEUTICALS LTD - Announcements

Recce Pharmaceuticals Ltd is an Australia-based company engaged in the development and... Recce Pharmaceuticals Ltd is an Australia-based company engaged in the development and commercialization of a new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. The Company's anti-infective pipeline includes three broad-spectrum, synthetic polymer anti-infectives: RECCE 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE 435 as an orally administered therapy for bacterial infections; and RECCE 529 for viral infections. Through their multi-layered mechanisms of action, the Company's anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses. All RECCE compounds are water soluble at all pH levels in their liquid form.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk

RCE Appendix 3B22/06/17
RCE Recce constructs automated manufacturing facility to supportPRICE SENSITIVE22/06/17
RCE Recce secures up to A$6.05 million investment agreement withPRICE SENSITIVE16/06/17
RCE Recce moves closer to clinical study applicationPRICE SENSITIVE19/05/17
RCE Appendic 4G16/05/17
RCE Appendix 4C - quarterlyPRICE SENSITIVE28/04/17
RCE Recce calls for Australian investment in R&D to develop new19/04/17
RCE Operational UpdatePRICE SENSITIVE10/04/17
RCE Data from large animal study shows RECCE 327 well toleratedPRICE SENSITIVE27/03/17
RCE Ceasing to be a substantial holder15/03/17
RCE Ceasing to be a substantial holder15/03/17
RCE Change of Director's Interest Notice09/03/17
RCE Appendix 4D and Interim Financial StatementsPRICE SENSITIVE28/02/17
RCE Microscopy Images of its Synthetic Antibiotic in Action DestPRICE SENSITIVE24/02/17
RCE Recce to suspend anti-cancer programPRICE SENSITIVE23/02/17
RCE Ceasing to be a substantial holder07/02/17
RCE Operational Update and Quarterly Cash FlowPRICE SENSITIVE30/01/17
RCE Director Appointment/Resignation23/01/17
RCE Response to ASX Price QueryPRICE SENSITIVE18/01/17
RCE Lead compound reduces illness in mice infected by E.coliPRICE SENSITIVE18/01/17
RCE Change of Director's Interest Notice16/01/17
RCE Appendix 3B16/01/17
RCE Request for Trading Halt16/01/17
RCE Trading HaltPRICE SENSITIVE16/01/17
RCE Encouraging anti-viral activity for lead compound RECCE 327PRICE SENSITIVE20/12/16
RCE Appendix 3B25/11/16
RCE Results of Meeting23/11/16
RCE AGM Presentation22/11/16
RCE Director Resignation22/11/16
RCE Pre-clinical toxicology and efficacy testing-RCE.AX PRICE SENSITIVE02/11/16
RCE Operational Update and Quarterly Cash Flow-RCE.AX PRICE SENSITIVE31/10/16
RCE Annual Report to shareholders-RCE.AX 21/10/16
RCE Notice of Annual General Meeting/Proxy Form-RCE.AX 21/10/16
RCE Appendix 4E and Financial Report-RCE.AX PRICE SENSITIVE28/08/16
RCE Appendix 4E and Financial Report-RCE.AX PRICE SENSITIVE25/08/16
RCE Dose Ranging in Mice - Repeated Success-RCE.AX PRICE SENSITIVE15/08/16
RCE Broker Presentation-RCE.AX 08/08/16
RCE Change in substantial holding-RCE.AX 01/08/16
RCE Appendix 4C - quarterly-RCE.AX PRICE SENSITIVE29/07/16
RCE Manufacturing Milestones and New Head Office-RCE.AX 28/07/16
RCE Successful Test Results for Genetic Toxicity-RCE.AX PRICE SENSITIVE20/07/16
RCE Change of Director's Interest Notice-RCE.AX 15/07/16
RCE Appendix 3B-RCE.AX 15/07/16
RCE Anti-viral Activity-RCE.AX PRICE SENSITIVE13/07/16
RCE Update on Testing Schedules-RCE.AX PRICE SENSITIVE21/06/16
RCE Appendix 3B-RCE.AX 14/06/16
RCE Appendix 3B-RCE.AX 07/06/16
RCE Pharma Executive Appointed to Recce Board-RCE.AX 27/05/16
RCE Encouraging Results from Safety Test-RCE.AX PRICE SENSITIVE25/05/16
RCE Shares to be released from Escrow-RCE.AX 23/05/16
RCE Director Appointment/Resignation-RCE.AX 16/05/16
RCE Shares to be Released from Escrow-RCE.AX 10/05/16
RCE Recce - The Way Forward-RCE.AX PRICE SENSITIVE03/05/16
RCE Appendix 4C - quarterly-RCE.AX PRICE SENSITIVE27/04/16
RCE Final Directors Interest Notice-RCE.AX 11/04/16
RCE Progress Update-RCE.AX PRICE SENSITIVE11/04/16
RCE International Trade Mark Registrations-RCE.AX PRICE SENSITIVE06/04/16
RCE Anti-cancer ActivitiesPRICE SENSITIVE14/03/16
RCE Amendment to Appendix 3B29/02/16
RCE Appendix 4D and Half Year Financial StatementsPRICE SENSITIVE26/02/16
RCE Becoming a substantial holder17/02/16
RCE Change of Director's Interest Notice16/02/16
RCE Appendix 3B16/02/16
RCE Conversion of Performance Shares16/02/16
RCE Efficacy without ToxicityPRICE SENSITIVE02/02/16
RCE Appendix 4C - quarterlyPRICE SENSITIVE29/01/16
RCE Becoming a substantial holder28/01/16
RCE RECCE Antibiotic kills TB and GonorrhoeaPRICE SENSITIVE27/01/16
RCE Becoming a substantial holder25/01/16
RCE Becoming a substantial holder25/01/16
RCE Broker Presentation18/01/16
RCE Initial Director's Interest Notice15/01/16
RCE Initial Director's Interest Notice15/01/16
RCE Initial Director's Interest Notice15/01/16
RCE Initial Director's Interest Notice15/01/16
RCE Initial Director's Interest Notice15/01/16
RCE RECCE Antiobiotic Equal/Better than Commercial Antibiotic15/01/16
RCE RECCE Trademark Registered15/01/16
RCE Additional Patent DevelopmentsPRICE SENSITIVE15/01/16
RCE Patent Granted in ChinaPRICE SENSITIVE15/01/16
RCE Patent Family Confirmations13/01/16
RCE Terms and conditions of Company's performance shares13/01/16
RCE Restricted Securities Statement13/01/16
RCE Securities Trading Policy13/01/16
RCE Finncial Accounts - 30 June 2013, 30 June 2014, 30 June 201513/01/16
RCE Constitution13/01/16
RCE Prospectus13/01/16
RCE Appendix 1A and Information Form and Checklist13/01/16
RCE Top 20 shareholders13/01/16
RCE Distribution Schedule13/01/16
RCE Pre-Quotation Disclosure13/01/16
RCE ASX Notice13/01/16
RCE Admission to Official ListPRICE SENSITIVE13/01/16
RCE IPO Oversubscribed30/12/15
RCE Supplementary Prospectus25/11/15
RCE Further extension of Offer to 30 October 201521/10/15
RCE Extension of Prospectus Offer Period14/10/15
RCE Recce Limited - Financial Report for FY 30 June 201323/09/15
RCE Recce Limited - Financial Report for FY 30 June 201523/09/15
RCE Recce Limited - Financial Report for FY 30 June 201423/09/15
RCE Appendix 3B
22/06/17
RCE Recce constructs automated manufacturing facility to support
22/06/17PRICE SENSITIVE
RCE Recce secures up to A$6.05 million investment agreement with
16/06/17PRICE SENSITIVE
RCE Recce moves closer to clinical study application
19/05/17PRICE SENSITIVE
RCE Appendic 4G
16/05/17
RCE Appendix 4C - quarterly
28/04/17PRICE SENSITIVE
RCE Recce calls for Australian investment in R&D to develop new
19/04/17
RCE Operational Update
10/04/17PRICE SENSITIVE
RCE Data from large animal study shows RECCE 327 well tolerated
27/03/17PRICE SENSITIVE
RCE Ceasing to be a substantial holder
15/03/17
RCE Ceasing to be a substantial holder
15/03/17
RCE Change of Director's Interest Notice
09/03/17
RCE Appendix 4D and Interim Financial Statements
28/02/17PRICE SENSITIVE
RCE Microscopy Images of its Synthetic Antibiotic in Action Dest
24/02/17PRICE SENSITIVE
RCE Recce to suspend anti-cancer program
23/02/17PRICE SENSITIVE
RCE Ceasing to be a substantial holder
07/02/17
RCE Operational Update and Quarterly Cash Flow
30/01/17PRICE SENSITIVE
RCE Director Appointment/Resignation
23/01/17
RCE Response to ASX Price Query
18/01/17PRICE SENSITIVE
RCE Lead compound reduces illness in mice infected by E.coli
18/01/17PRICE SENSITIVE
RCE Change of Director's Interest Notice
16/01/17
RCE Appendix 3B
16/01/17
RCE Request for Trading Halt
16/01/17
RCE Trading Halt
16/01/17PRICE SENSITIVE
RCE Encouraging anti-viral activity for lead compound RECCE 327
20/12/16PRICE SENSITIVE
RCE Appendix 3B
25/11/16
RCE Results of Meeting
23/11/16
RCE AGM Presentation
22/11/16
RCE Director Resignation
22/11/16
RCE Pre-clinical toxicology and efficacy testing-RCE.AX
02/11/16PRICE SENSITIVE
RCE Operational Update and Quarterly Cash Flow-RCE.AX
31/10/16PRICE SENSITIVE
RCE Annual Report to shareholders-RCE.AX
21/10/16
RCE Notice of Annual General Meeting/Proxy Form-RCE.AX
21/10/16
RCE Appendix 4E and Financial Report-RCE.AX
28/08/16PRICE SENSITIVE
RCE Appendix 4E and Financial Report-RCE.AX
25/08/16PRICE SENSITIVE
RCE Dose Ranging in Mice - Repeated Success-RCE.AX
15/08/16PRICE SENSITIVE
RCE Broker Presentation-RCE.AX
08/08/16
RCE Change in substantial holding-RCE.AX
01/08/16
RCE Appendix 4C - quarterly-RCE.AX
29/07/16PRICE SENSITIVE
RCE Manufacturing Milestones and New Head Office-RCE.AX
28/07/16
RCE Successful Test Results for Genetic Toxicity-RCE.AX
20/07/16PRICE SENSITIVE
RCE Change of Director's Interest Notice-RCE.AX
15/07/16
RCE Appendix 3B-RCE.AX
15/07/16
RCE Anti-viral Activity-RCE.AX
13/07/16PRICE SENSITIVE
RCE Update on Testing Schedules-RCE.AX
21/06/16PRICE SENSITIVE
RCE Appendix 3B-RCE.AX
14/06/16
RCE Appendix 3B-RCE.AX
07/06/16
RCE Pharma Executive Appointed to Recce Board-RCE.AX
27/05/16
RCE Encouraging Results from Safety Test-RCE.AX
25/05/16PRICE SENSITIVE
RCE Shares to be released from Escrow-RCE.AX
23/05/16
RCE Director Appointment/Resignation-RCE.AX
16/05/16
RCE Shares to be Released from Escrow-RCE.AX
10/05/16
RCE Recce - The Way Forward-RCE.AX
03/05/16PRICE SENSITIVE
RCE Appendix 4C - quarterly-RCE.AX
27/04/16PRICE SENSITIVE
RCE Final Directors Interest Notice-RCE.AX
11/04/16
RCE Progress Update-RCE.AX
11/04/16PRICE SENSITIVE
RCE International Trade Mark Registrations-RCE.AX
06/04/16PRICE SENSITIVE
RCE Anti-cancer Activities
14/03/16PRICE SENSITIVE
RCE Amendment to Appendix 3B
29/02/16
RCE Appendix 4D and Half Year Financial Statements
26/02/16PRICE SENSITIVE
RCE Becoming a substantial holder
17/02/16
RCE Change of Director's Interest Notice
16/02/16
RCE Appendix 3B
16/02/16
RCE Conversion of Performance Shares
16/02/16
RCE Efficacy without Toxicity
02/02/16PRICE SENSITIVE
RCE Appendix 4C - quarterly
29/01/16PRICE SENSITIVE
RCE Becoming a substantial holder
28/01/16
RCE RECCE Antibiotic kills TB and Gonorrhoea
27/01/16PRICE SENSITIVE
RCE Becoming a substantial holder
25/01/16
RCE Becoming a substantial holder
25/01/16
RCE Broker Presentation
18/01/16
RCE Initial Director's Interest Notice
15/01/16
RCE Initial Director's Interest Notice
15/01/16
RCE Initial Director's Interest Notice
15/01/16
RCE Initial Director's Interest Notice
15/01/16
RCE Initial Director's Interest Notice
15/01/16
RCE RECCE Antiobiotic Equal/Better than Commercial Antibiotic
15/01/16
RCE RECCE Trademark Registered
15/01/16
RCE Additional Patent Developments
15/01/16PRICE SENSITIVE
RCE Patent Granted in China
15/01/16PRICE SENSITIVE
RCE Patent Family Confirmations
13/01/16
RCE Terms and conditions of Company's performance shares
13/01/16
RCE Restricted Securities Statement
13/01/16
RCE Securities Trading Policy
13/01/16
RCE Finncial Accounts - 30 June 2013, 30 June 2014, 30 June 2015
13/01/16
RCE Constitution
13/01/16
RCE Prospectus
13/01/16
RCE Appendix 1A and Information Form and Checklist
13/01/16
RCE Top 20 shareholders
13/01/16
RCE Distribution Schedule
13/01/16
RCE Pre-Quotation Disclosure
13/01/16
RCE ASX Notice
13/01/16
RCE Admission to Official List
13/01/16PRICE SENSITIVE
RCE IPO Oversubscribed
30/12/15
RCE Supplementary Prospectus
25/11/15
RCE Further extension of Offer to 30 October 2015
21/10/15
RCE Extension of Prospectus Offer Period
14/10/15
RCE Recce Limited - Financial Report for FY 30 June 2013
23/09/15
RCE Recce Limited - Financial Report for FY 30 June 2015
23/09/15
RCE Recce Limited - Financial Report for FY 30 June 2014
23/09/15
(20min delay)
Last
43.0¢
Change
-0.010(2.27%)
Mkt cap ! $118.1M
Open High Low Value Volume
44.0¢ 44.5¢ 43.0¢ $130.8K 297.2K

Buyers (Bids)

No. Vol. Price($)
4 31774 43.0¢
 

Sellers (Offers)

Price($) Vol. No.
44.0¢ 13243 1
View Market Depth
Last trade - 16.10pm 02/12/2024 (20 minute delay) ?
Last
44.0¢
  Change
-0.010 ( 1.12 %)
Open High Low Volume
44.0¢ 44.5¢ 44.0¢ 87918
Last updated 14.19pm 02/12/2024 ?
RCE (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.